Prognostic Impact of Serum Albumin Levels at Diagnosis in Patients with Chronic Lymphocytic Leukemia

Background/Objectives: Chronic lymphocytic leukemia (CLL) displays substantial clinical heterogeneity, yet access to genomic prognostic testing remains limited in many real-world and resource-constrained settings. Readily available biomarkers that reflect disease biology are therefore clinically valuable. Serum albumin, an inexpensive marker associated with systemic inflammation and tumor burden, has shown emerging prognostic potential. This study evaluated the impact of baseline albumin on time to first treatment (TTFT) and overall survival (OS) in CLL. Methods: We retrospectively analyzed adult patients with confirmed CLL treated at a single tertiary center. Baseline demographic, clinical, and laboratory features were recorded, and serum albumin was dichotomized at 4 g/dL. TTFT and OS were estimated using the Kaplan–Meier methodology. Variables with p < 0.1 in univariate analyses were included in multivariate Cox regression models. Results: A total of 230 patients were included. The median age at diagnosis was 62.5 years; 52.2% were male, and 14.8% had serum albumin